A pioneering technology
BMX-502 is a new-generation bispecific antibody that engages and activates MAIT cells (Mucosal Associated Invariant T-cells). These cells, first identified in 1999 by Dr. Olivier Lantz of the Institut Curie, are a subpopulation of unconventional T lymphocytes that are present throughout the body. They are able to proliferate, migrate and infiltrate solid tumors, making them particularly effective in targeting cancer cells.
A strategic partnership
The partnership between Biomunex and Institut Curie has highlighted a novel therapeutic approach based on the unique properties of MAIT cells. In March 2024, Biomunex signed an exclusive licensing agreement with Institut Curie for the clinical development of innovative bispecific antibodies capable of mobilizing MAIT cells to destroy cancer cells.
Towards global commercialization
The signing of this exclusive global licensing agreement with Ipsen will fast-track the placing on the market of BMX-502. Biomunex will finalize the studies required for clinical study authorization in the United States, while Ipsen will be responsible for the preparation of Phase I, future clinical development and global commercialization activities.
Hope for patients
“This licensing agreement with Ipsen, a leading global player in oncology, illustrates not only the relevance of this technology, but also that of our technology transfer strategy,” says Dr. Cécile Campagne, Director of Valorization and Industrial Partnerships at Institut Curie. BMX-502 represents a real breakthrough in the development of breakthrough immunotherapies for the treatment of cancer, offering new hope to patients with solid tumors.
Cancer statistics in France
- Incidence: In 2025, the estimated incidence of cancer in France is slightly higher than the EU average. More than 160,000 new cases of cancer are diagnosed each year.
- Mortality: Cancer remains the leading cause of death in France, with more than 160,000 deaths per year.
- Prevalence: Around 3.8 million people are living with a cancer diagnosis in France.
- Survival: One in two cancer patients can be cured, thanks to medical advances.